IBDEI26M ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36638,1,3,0)
 ;;=3^Von Willebrand's disease
 ;;^UTILITY(U,$J,358.3,36638,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,36638,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,36639,0)
 ;;=D68.311^^169^1853^2
 ;;^UTILITY(U,$J,358.3,36639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36639,1,3,0)
 ;;=3^Acquired hemophilia
 ;;^UTILITY(U,$J,358.3,36639,1,4,0)
 ;;=4^D68.311
 ;;^UTILITY(U,$J,358.3,36639,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,36640,0)
 ;;=D68.312^^169^1853^4
 ;;^UTILITY(U,$J,358.3,36640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36640,1,3,0)
 ;;=3^Antiphospholipid antibody with hemorrhagic disorder
 ;;^UTILITY(U,$J,358.3,36640,1,4,0)
 ;;=4^D68.312
 ;;^UTILITY(U,$J,358.3,36640,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,36641,0)
 ;;=D68.318^^169^1853^13
 ;;^UTILITY(U,$J,358.3,36641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36641,1,3,0)
 ;;=3^Hemorrhagic disord d/t intrns circ anticoag,antib,inhib NEC
 ;;^UTILITY(U,$J,358.3,36641,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,36641,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,36642,0)
 ;;=D65.^^169^1853^7
 ;;^UTILITY(U,$J,358.3,36642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36642,1,3,0)
 ;;=3^Disseminated intravascular coagulation
 ;;^UTILITY(U,$J,358.3,36642,1,4,0)
 ;;=4^D65.
 ;;^UTILITY(U,$J,358.3,36642,2)
 ;;=^5002352
 ;;^UTILITY(U,$J,358.3,36643,0)
 ;;=D68.32^^169^1853^12
 ;;^UTILITY(U,$J,358.3,36643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36643,1,3,0)
 ;;=3^Hemorrhagic disord d/t extrinsic circulating anticoagulants
 ;;^UTILITY(U,$J,358.3,36643,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,36643,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,36644,0)
 ;;=D68.4^^169^1853^1
 ;;^UTILITY(U,$J,358.3,36644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36644,1,3,0)
 ;;=3^Acquired coagulation factor deficiency
 ;;^UTILITY(U,$J,358.3,36644,1,4,0)
 ;;=4^D68.4
 ;;^UTILITY(U,$J,358.3,36644,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,36645,0)
 ;;=D68.8^^169^1853^5
 ;;^UTILITY(U,$J,358.3,36645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36645,1,3,0)
 ;;=3^Coagulation Defects NEC
 ;;^UTILITY(U,$J,358.3,36645,1,4,0)
 ;;=4^D68.8
 ;;^UTILITY(U,$J,358.3,36645,2)
 ;;=^5002363
 ;;^UTILITY(U,$J,358.3,36646,0)
 ;;=D68.9^^169^1853^6
 ;;^UTILITY(U,$J,358.3,36646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36646,1,3,0)
 ;;=3^Coagulation Defects,Unspec
 ;;^UTILITY(U,$J,358.3,36646,1,4,0)
 ;;=4^D68.9
 ;;^UTILITY(U,$J,358.3,36646,2)
 ;;=^5002364
 ;;^UTILITY(U,$J,358.3,36647,0)
 ;;=D69.1^^169^1853^22
 ;;^UTILITY(U,$J,358.3,36647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36647,1,3,0)
 ;;=3^Qualitative platelet defects
 ;;^UTILITY(U,$J,358.3,36647,1,4,0)
 ;;=4^D69.1
 ;;^UTILITY(U,$J,358.3,36647,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,36648,0)
 ;;=D47.3^^169^1853^8
 ;;^UTILITY(U,$J,358.3,36648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36648,1,3,0)
 ;;=3^Essential (hemorrhagic) thrombocythemia
 ;;^UTILITY(U,$J,358.3,36648,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,36648,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,36649,0)
 ;;=D69.0^^169^1853^3
 ;;^UTILITY(U,$J,358.3,36649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36649,1,3,0)
 ;;=3^Allergic purpura
 ;;^UTILITY(U,$J,358.3,36649,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,36649,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,36650,0)
 ;;=D69.2^^169^1853^19
 ;;^UTILITY(U,$J,358.3,36650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36650,1,3,0)
 ;;=3^Nonthrombocytopenic purpura NEC
 ;;^UTILITY(U,$J,358.3,36650,1,4,0)
 ;;=4^D69.2
 ;;^UTILITY(U,$J,358.3,36650,2)
 ;;=^5002366
 ;;^UTILITY(U,$J,358.3,36651,0)
 ;;=D69.3^^169^1853^18
 ;;^UTILITY(U,$J,358.3,36651,1,0)
 ;;=^358.31IA^4^2
